Targeting AXL can effectively overcome c-Met-induced therapeutic resistance in renal cancer and promote tumor cell death through increased oxidative stress

Authors:

Abstract
No abstract available
Funding Information
  • National Institutes of Health (R01CA262577)
  • US Department of Defense (W81XWH-21-1-0339)
  • US Department of Defense (W81XWH-21-1-0234)
  • US Department of Defense (W81XWH-19-1-0554)
  • Deutsche Forschungsgemeinschaft (404527522)
  • Dana-Farber Cancer Institute
  • Dana Foundation
  • Harvard Medical School
  • American Society of Nephrology
  • Else Kröner-Fresenius-Stiftung
  • National Cancer Coalition
  • Medical Research Foundation
  • Exelixis
  • National Institutes of Health National Cancer Institute (5P30CA006516-56)
  • National Institutes of Health National Cancer Institute (R03CA230944)
  • National Institutes of Health National Cancer Institute (R01CA251555)

This publication has 89 references indexed in Scilit: